for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hua Medicine

2552.HK

Latest Trade

5.98HKD

Change

0.18(+3.10%)

Volume

766,500

Today's Range

5.85

 - 

6.08

52 Week Range

2.47

 - 

9.00

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5.80
Open
5.99
Volume
766,500
3M AVG Volume
22.76
Today's High
6.08
Today's Low
5.85
52 Week High
9.00
52 Week Low
2.47
Shares Out (MIL)
949.63
Market Cap (MIL)
6,287.17
Forward P/E
-7.33
Dividend (Yield %)
--

Next Event

Hua Medicine Annual Shareholders Meeting

Latest Developments

More

Hua Medicine Says Unit Enters Collaboration Agreement With Bayer Healthcare

Hua Medicine Posts HY Loss Before Tax Of About Rmb173.5 Million

Hua Medicine Says Dorzagliatin's Phase III Metformin Combination Trial Met Primary Efficacy And Safety End Point

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hua Medicine

Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.

Industry

Biotechnology & Drugs

Contact Info

Hua Medicine, 275 Ai Di Sheng Road

SHANGHAI, SHA

201203

China

+86.21.58869997

Executive Leadership

Robert T. Nelsen

Non-Executive Chairman of the Board

Li Chen

Chief Executive Officer, Founder, Chief Scientific Officer, Executive Director

Chien Cheng Lin

Chief Financial Officer, Executive Vice President, Executive Director

Yunlong Du

Senior Vice President - Regulatory, Clinical and Manufacture Department and Drug Safety and Pharmacovigilance Department

Yong-Guo Li

Senior Vice President - Chemical Manufacturing Control

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (CNY)

2018

-0.832

2019

-0.450

2020(E)

-0.662
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
9.53
LT Debt To Equity (MRQ)
7.92
Return on Investment (TTM)
-32.61
Return on Equity (TTM)
-30.40

Latest News

Latest News

BRIEF-Hua Medicine Says Dorzagliatin's Phase III Metformin Combination Trial Met Primary Efficacy And Safety End Point

* HUA MEDICINE- DORZAGLIATIN'S PHASE III METFORMIN COMBINATION TRIAL MET PRIMARY EFFICACY AND SAFETY END POINT Source text for Eikon: Further company coverage:

BRIEF-Hua Medicine Announces Positive Results Of Combination Study Of Dorzagliatin With Empagliflozin (A Sglt-2 Inhibitor)

* ANNOUNCES POSITIVE RESULTS OF COMBINATION STUDY OF DORZAGLIATIN WITH EMPAGLIFLOZIN (A SGLT-2 INHIBITOR)

BRIEF-Hua Medicine Says Business Ops In China Impacted By Outbreak Of Novel Coronavirus Since Latter Half Of Jan

* HUA MEDICINE - BUSINESS OPERATIONS IN CHINA IMPACTED BY OUTBREAK OF NOVEL CORONAVIRUS SINCE LATTER HALF OF JAN

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up